Antibody Libraries

A Library for Every Discovery Challenge

Our antibody libraries combine exceptional diversity with human relevance — providing the foundation for the discovery of high-quality binders across diverse targets. From fully human naïve and immune libraries to VHH and paired libraries, we offer the right starting point for every discovery challenge.

icon-antibodylibraries-gelb
yumab-libraries

The Human Antibody Repertoire in One Tube –

Utilizing Nature’s Immune Library for Drug Discovery

Antibody discovery is all about finding the needle in the haystack, i.e. the right sequence that unlocks access to your target and mechanism of action. YUMAB’s broad library services and advanced in vitro selection technologies facilitate the identification of novel antibodies and the optimization of existing lead candidates against any target at a high success rate.

Universal YUMAB® libraries contain natural antibody sequences, which are close to the human germline repertoire. These antibody sequences are pre-selected in the human body for low toxicity, immunogenicity, and high productivity, which makes them perfect for the development of therapeutic drugs.

Our Libraries for Your Antibody Therapeutics

YUMAB’s antibody libraries are large, highly diverse collections of antibody gene sequences, derived from both natural and immune repertoires, and cloned into vectors optimized for phenotypic screening through phage or mammalian display. In addition to our antibody discovery and development services, we also offer custom library generation.

Built for any target

Our universal, fully human libraries encompass all antibody frameworks without germline or CDR restrictions. This enables the discovery of antibodies against virtually any target with broad epitope and affinity coverage.

Small, stable and convenient building blocks for bi- and multi-specific formats

YUMAB generates antigen-specific single domain (VHH) antibody libraries from immunized new world camelids. For immunization against complex multi-pass TMPs, we use a unique llama-derived cell line transfected with the target of interest to address even challenging targets. These high affinity in-vivo optimized VHH antibodies are used as building blocks of the next generation of multispecific antibody drugs.

Bridging in vivo and in vitro

YUMAB’s cutting-edge microfluidic technology for B cell encapsulation allows the isolation of paired heavy and light chains to generate naturally paired antibody Libraries.

Questions and Answers

We offer a broad range of antibody libraries:
· Ready-to-use fully human naïve libraries
· Naive cat and dog libraries
· Customized immune libraries, which are generated from immunized New World Camelids (VHH) and other animals or human patients. These can also be constructed as paired libraries, preserving the heavy and light chain pairing during library construction as it was formed in vivo.
The optimal library depends on the target and project requirements. YUMAB offers a diverse range of library sources and technologies, allowing us to select the most suitable approach for each project. We assess factors such as target biology, species homology, epitope requirements, and intended application to define the right discovery strategy.
Yes. We can design and construct customized antibody libraries tailored to specific project requirements. Libraries can be generated from virtually any species, including from immunized animals or human donors. Alternatively, antibody repertoires can be customized through targeted CDR and sequence design. For AI-driven library generation, we can use provided sequence information to design synthetic libraries with defined sequence diversity.
If the same target is investigated in different projects, YUMAB uses a different antibody library for each project. By switching the library, we access different sequence spaces and generate unique antibody sequences tailored to each client’s specific requirements. In addition, all identified antibody sequences are recorded in our in-house database and cross-checked to determine whether the same sequence has been identified previously.

Talk to a Scientist

Dr. Phillipp Kuhn
VP Services & Operations

Discuss Your Project

We typically reply within 1-2 business days.